The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
Riccardo Lencioni
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer
Research Funding - Bayer
Josep M. Llovet
Consultant or Advisory Role - Bayer; Onyx
Honoraria - Bayer
Research Funding - Bayer
Guohong Han
No relevant relationships to disclose
Won-Young Tak
No relevant relationships to disclose
Jiamei Yang
No relevant relationships to disclose
Marie-Aude Leberre
Employment or Leadership Position - Bayer
Woody Niu
Employment or Leadership Position - Bayer
Kate Nicholson
Employment or Leadership Position - Bayer
Gerold Meinhardt
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Jordi Bruix
Consultant or Advisory Role - ArQule; Bayer; Biocompatibles International; Bristol-Myers Squibb; GlaxoSmithKline; Kowa ; Novartis
Honoraria - Bayer
Research Funding - Bayer